PMID- 32264719
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210423
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Dec
TI  - Prospects and challenges of extracellular vesicle-based drug delivery system: 
      considering cell source.
PG  - 585-598
LID - 10.1080/10717544.2020.1748758 [doi]
AB  - Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic 
      bodies, are nanosized membrane vesicles derived from most cell types. Carrying 
      diverse biomolecules from their parent cells, EVs are important mediators of 
      intercellular communication and thus play significant roles in physiological and 
      pathological processes. Owing to their natural biogenesis process, EVs are 
      generated with high biocompatibility, enhanced stability, and limited 
      immunogenicity, which provide multiple advantages as drug delivery systems (DDSs) 
      over traditional synthetic delivery vehicles. EVs have been reported to be used 
      for the delivery of siRNAs, miRNAs, protein, small molecule drugs, nanoparticles, 
      and CRISPR/Cas9 in the treatment of various diseases. As a natural drug delivery 
      vectors, EVs can penetrate into the tissues and be bioengineered to enhance the 
      targetability. Although EVs' characteristics make them ideal for drug delivery, 
      EV-based drug delivery remains challenging, due to lack of standardized isolation 
      and purification methods, limited drug loading efficiency, and insufficient 
      clinical grade production. In this review, we summarized the current knowledge on 
      the application of EVs as DDS from the perspective of different cell origin and 
      weighted the advantages and bottlenecks of EV-based DDS.
FAU - Meng, Wanrong
AU  - Meng W
AD  - Department of Stomatology, School of Medicine, Sichuan Cancer Hospital, Sichuan 
      Key Laboratory of Radiation Oncology, University of Electronic Science and 
      Technology of China, Chengdu, PR China.
FAU - He, Chanshi
AU  - He C
AD  - Department of Stomatology, School of Medicine, Sichuan Cancer Hospital, Sichuan 
      Key Laboratory of Radiation Oncology, University of Electronic Science and 
      Technology of China, Chengdu, PR China.
FAU - Hao, Yaying
AU  - Hao Y
AD  - Department of Stomatology, School of Medicine, Sichuan Cancer Hospital, Sichuan 
      Key Laboratory of Radiation Oncology, University of Electronic Science and 
      Technology of China, Chengdu, PR China.
FAU - Wang, Linlin
AU  - Wang L
AD  - Department of Stomatology, School of Medicine, Sichuan Cancer Hospital, Sichuan 
      Key Laboratory of Radiation Oncology, University of Electronic Science and 
      Technology of China, Chengdu, PR China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Stomatology, School of Medicine, Sichuan Cancer Hospital, Sichuan 
      Key Laboratory of Radiation Oncology, University of Electronic Science and 
      Technology of China, Chengdu, PR China.
FAU - Zhu, Guiquan
AU  - Zhu G
AD  - Department of Stomatology, School of Medicine, Sichuan Cancer Hospital, Sichuan 
      Key Laboratory of Radiation Oncology, University of Electronic Science and 
      Technology of China, Chengdu, PR China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Drug Carriers/metabolism
MH  - Drug Delivery Systems/*methods
MH  - *Extracellular Vesicles
MH  - Humans
PMC - PMC7178886
OTO - NOTNLM
OT  - Drug delivery
OT  - exosomes
OT  - extracellular vesicles
OT  - microvesicles
EDAT- 2020/04/09 06:00
MHDA- 2021/02/03 06:00
PMCR- 2020/04/08
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
PHST- 2020/04/08 00:00 [pmc-release]
AID - 1748758 [pii]
AID - 10.1080/10717544.2020.1748758 [doi]
PST - ppublish
SO  - Drug Deliv. 2020 Dec;27(1):585-598. doi: 10.1080/10717544.2020.1748758.